glp-1 parkinson's disease lancet Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative treatment GLP-1 receptor agonists in Parkinson's

HOW IT WORKS BPC-157 helps grow new blood vessels to bring nutrients to injured areas, makes repair cells move faster to injury sites, and protects tissues throughout the body

These treatments include the hangover cure, jet lag cure, immune boost, re-hydration, weight loss and beauty iv therapy

The phase 3 TRIUMPH-4 data showed these rates at 9 mg and 12 mg doses respectively: Nausea: 38.1% and 43.2% (vs 10.7% placebo) Diarrhea: 34.7% and 33.1% (vs 13.4% placebo) Constipation: 21.8% and 25.0% (vs 8.7% placebo) Vomiting: 20.4% and 20.9% (vs placebo) These numbers are higher than cagrilintide monotherapy across the board

Their analysis found that GLP-1 users reported chronic cough roughly 29% more often than patients taking DPP-4 inhibitors, SGLT2 inhibitors, or sulfonylureas

doi: 10.1107/S2053230X17011840 56 HummelW.GrgerH